Literature DB >> 17541498

Soluble receptor activator of NFkappa B-ligand and osteoprotegerin in rheumatoid arthritis - relationship with bone mineral density, disease activity and bone turnover.

P Oelzner1, S Franke2, G Lehmann2, T Eidner2, A Müller2, G Wolf2, G Hein2.   

Abstract

The aim of our study was to investigate determinants of bone mineral density (BMD) measured by dual X-ray absorptiometry at the lumbar spine (BMD-LS) and at the femoral neck (BMD-FN) in patients with rheumatoid arthritis (RA) with special respect to bone resorbing proinflammatory cytokines and their physiological antagonists. In 142 RA patients the following parameters were measured in parallel with BMD: serum levels of soluble receptor activator of nuclear factor kappa-B-ligand (sRANKL), osteoprotegerin (OPG), interleukin (IL)-6, soluble glycoprotein 130 (sgp130), 25-hydroxyvitamin D3 (25OHD(3)), 1,25-dihydroxyvitamin D3 (1,25[OH](2)D(3)), intact parathyroid hormone, osteocalcin, ionized calcium, renal excretion of pyridinolin and deoxypyridinolin, C-reactive protein, and erythrocyte sedimentation rate (ESR). No significant differences of sRANKL, OPG, IL-6, and spg130 were found between patients with osteoporosis (47.9% of patients), osteopenia (36.6%), and normal BMD (15.5%). However, total sRANKL was significantly higher in postmenopausal women with osteoporosis at FN than in those without (p < 0.05) and showed a negative correlation with BMD-LS in patients older than 60 years (p = 0.01). BMD-LS and BMD-FN (p < 0.001) and total sRANKL (p < 0.01) were negatively related with the age of the patients. Only IL-6 (positive correlation, p < 0.001) and 1,25(OH)(2)D(3) (negative correlation, p < 0.001) but not sRANKL, OPG, and sgp130 were related to disease activity. Using multiple linear regression analysis, menopause was identified as the crucial negative determinant of BMD-LS (R (2) = 0.94, p = 0.001), whereas cumulative glucocorticoid dose (beta = -0.80, p = 0.001) and ESR (beta = -0.44, p = 0.016) were the negative determinants of BMD-FN (R (2) = 0.86, p = 0.001). The results indicate that influences of age and gender must be considered in investigations on the relationship between BMD and sRANKL in RA and that high serum levels of sRANKL seems to be associated with osteoporosis only in subgroups of RA patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17541498     DOI: 10.1007/s10067-007-0639-5

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  50 in total

Review 1.  The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption.

Authors:  L C Hofbauer; S Khosla; C R Dunstan; D L Lacey; W J Boyle; B L Riggs
Journal:  J Bone Miner Res       Date:  2000-01       Impact factor: 6.741

2.  Levels of serum and synovial fluid pyridinium crosslinks in patients with rheumatoid arthritis.

Authors:  Y Furumitsu; M Inaba; K Yukioka; M Yukioka; Y Kumeda; Y Azuma; T Ohta; T Ochi; Y Nishizawa; H Morii
Journal:  J Rheumatol       Date:  2000-01       Impact factor: 4.666

3.  Osteoclastogenesis in iliac bone marrow of patients with rheumatoid arthritis.

Authors:  Y Toritsuka; N Nakamura; S B Lee; J Hashimoto; N Yasui; K Shino; T Ochi
Journal:  J Rheumatol       Date:  1997-09       Impact factor: 4.666

4.  Quantitative analysis of pyridinium crosslinks of collagen in the synovial fluid of patients with rheumatoid arthritis using high-performance liquid chromatography.

Authors:  A Müller; G Hein; S Franke; D Herrmann; S Henzgen; A Roth; G Stein
Journal:  Rheumatol Int       Date:  1996       Impact factor: 2.631

5.  A novel molecular mechanism modulating osteoclast differentiation and function.

Authors:  H Yasuda; N Shima; N Nakagawa; K Yamaguchi; M Kinosaki; M Goto; S I Mochizuki; E Tsuda; T Morinaga; N Udagawa; N Takahashi; T Suda; K Higashio
Journal:  Bone       Date:  1999-07       Impact factor: 4.398

6.  Fractures in rheumatoid arthritis: an evaluation of associated risk factors.

Authors:  B A Michel; D A Bloch; F Wolfe; J F Fries
Journal:  J Rheumatol       Date:  1993-10       Impact factor: 4.666

7.  Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice.

Authors:  Georg Schett; Kurt Redlich; Silvia Hayer; Jochen Zwerina; Brad Bolon; Colin Dunstan; Birgit Görtz; Andreas Schulz; Helga Bergmeister; Giorgos Kollias; Günter Steiner; Josef S Smolen
Journal:  Arthritis Rheum       Date:  2003-07

8.  Down-regulation by nuclear factor kappaB of human 25-hydroxyvitamin D3 1alpha-hydroxylase promoter.

Authors:  Regina Ebert; Marlena Jovanovic; Matthias Ulmer; Doris Schneider; Jutta Meissner-Weigl; Jerzy Adamski; Franz Jakob
Journal:  Mol Endocrinol       Date:  2004-07-08

9.  Serum osteoprotegerin and receptor activator of nuclear factors kB (RANKL) concentrations in normal children and in children with pubertal precocity, Turner's syndrome and rheumatoid arthritis.

Authors:  F Buzi; G Maccarinelli; B Guaragni; F Ruggeri; G Radetti; A Meini; E Mazzolari; D Cocchi
Journal:  Clin Endocrinol (Oxf)       Date:  2004-01       Impact factor: 3.478

10.  Osteoclastic activation is the principal mechanism leading to secondary osteoporosis in rheumatoid arthritis.

Authors:  A Gough; P Sambrook; J Devlin; A Huissoon; C Njeh; S Robbins; T Nguyen; P Emery
Journal:  J Rheumatol       Date:  1998-07       Impact factor: 4.666

View more
  8 in total

1.  Association of estrogen receptor β and estrogen-related receptor α gene polymorphisms with bone mineral density in postmenopausal women.

Authors:  Amira Shoukry; Sally M Shalaby; Rasha L Etewa; Hanan S Ahmed; Hossam M Abdelrahman
Journal:  Mol Cell Biochem       Date:  2015-04-24       Impact factor: 3.396

2.  Osteoprotegerin and RANKL in the pathogenesis of rheumatoid arthritis-induced osteoporosis.

Authors:  Shengqian Xu; Yu Wang; Jingqiu Lu; Jianhua Xu
Journal:  Rheumatol Int       Date:  2011-11-06       Impact factor: 2.631

Review 3.  Levels of osteoprotegerin (OPG) and receptor activator for nuclear factor kappa B ligand (RANKL) in serum: are they of any help?

Authors:  Doris Wagner; Astrid Fahrleitner-Pammer
Journal:  Wien Med Wochenschr       Date:  2010-08-16

4.  Serum RANKL, osteoprotegerin (OPG), and RANKL/OPG ratio in nephrotic children.

Authors:  Anna Wasilewska; Agnieszka Rybi-Szuminska; Walentyna Zoch-Zwierz
Journal:  Pediatr Nephrol       Date:  2010-07-04       Impact factor: 3.714

5.  Macrophage migration inhibitory factor enhances osteoclastogenesis through upregulation of RANKL expression from fibroblast-like synoviocytes in patients with rheumatoid arthritis.

Authors:  Hae-Rim Kim; Kyoung-Woon Kim; Hong Geun Jung; Kwang-Sup Yoon; Hye-Jwa Oh; Mi-La Cho; Sang-Heon Lee
Journal:  Arthritis Res Ther       Date:  2011-03-14       Impact factor: 5.156

6.  Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY.

Authors:  Anita Boyapati; Jérôme Msihid; Stefano Fiore; Janet van Adelsberg; Neil M H Graham; Jennifer D Hamilton
Journal:  Arthritis Res Ther       Date:  2016-10-06       Impact factor: 5.156

7.  Assessment of Serum sRANKL, sRANKL/OPG Ratio, and Other Bone Turnover Markers with the Estimated 10-Year Risk of Major and Hip Osteoporotic Fractures in Rheumatoid Arthritis: A Cross-Sectional Study.

Authors:  C A Nava-Valdivia; J M Ponce-Guarneros; A M Saldaña-Cruz; E G Corona-Sanchez; M Ramirez-Villafaña; E E Perez-Guerrero; J D Murillo-Saich; B Contreras-Haro; M L Vazquez-Villegas; F Gonzalez-Ponce; D Bonilla-Lara; H Jacobo-Cuevas; J D Centeno-Valadez; G Echeverria-Gonzalez; S Cerpa-Cruz; M F Alcaraz-Lopez; E G Cardona-Muñoz; M Salazar-Paramo; L Gonzalez-Lopez; J I Gamez-Nava
Journal:  Biomed Res Int       Date:  2021-08-30       Impact factor: 3.411

Review 8.  Mechanisms of Systemic Osteoporosis in Rheumatoid Arthritis.

Authors:  Peter Pietschmann; Maria Butylina; Katharina Kerschan-Schindl; Wolfgang Sipos
Journal:  Int J Mol Sci       Date:  2022-08-05       Impact factor: 6.208

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.